Formulations of L-ornithine phenylacetate
Some embodiments of the present application are directed to oral formulations of L-ornithine phenylacetate and methods of using the same. These oral formulations offer alternative administration route than the standard intravenous administration of L-ornithine phenylacetate for treating hyperammonemia in patients having various acute and chronic liver diseases and disorders, for example, acute liver failure, liver cirrhosis, liver decompensation, portal hypertension, hepatic encephalopathy, or patients with urea cycle disorders.
1. A method for treating or ameliorating hyperammonemia, comprising orally administering to a subject in need thereof an immediate release pharmaceutical formulation comprising L-ornithine phenylacetate in a daily oral dosage of about 8 g to about 12 g.
2. The method of claim 1 , wherein the subject has liver cirrhosis with a classification of Child-Pugh class A, B or C.
3. The method of claim 1 , wherein the subject has one or more conditions selected from the group consisting of hepatic encephalopathy, portal hypertension, and urea cycle disorder.
4. The method of claim 1 , comprising orally administering 2 to 5 unit dosage forms each comprising from about 0.5 g to about 2 g L-ornithine phenylacetate two or three times a day.
5. The method of claim 1 , wherein the immediate release pharmaceutical formulation comprising L-ornithine phenylacetate is administered in a daily dosage of about 8 g to about 10 g.
6. The method of claim 5 , wherein the immediate release pharmaceutical formulation is administered two times a day, each time administering about 4 g to about 5 g L-ornithine phenylacetate.
7. The method of claim 6 , wherein each time the immediate release pharmaceutical formulation is administered in 4 unit dosage forms each comprising about 1 g of L-ornithine phenylacetate.
8. The method of claim 1 , wherein the immediate release pharmaceutical formulation is administered two times a day, each time administering about 4 g to about 6 g L-ornithine phenylacetate.
9. A method for treating or ameliorating hyperammonemia, comprising orally administering to a subject in need thereof an immediate release pharmaceutical formulation comprising L-ornithine phenylacetate in a daily dosage of about 8 g to about 12 g, wherein said administration provides a plasma Cmax of phenylacetic acid ranging from about 10 μg/mL to about 150 μg/mL.
10. The method of claim 9 , wherein the administration provides a plasma Cmax of phenylacetylglutamine ranging from about 5 μg/mL to about 100 μg/mL.
11. The method of claim 9 , wherein the subject has liver cirrhosis with a classification of Child-Pugh class A, B or C.
12. The method of claim 9 , wherein the subject has one or more conditions selected from the group consisting of hepatic encephalopathy, portal hypertension, and urea cycle disorder.
13. The method of claim 9 , comprising orally administering 2 to 5 unit dosage forms each comprising from about 0.5 g to about 2 g of L-ornithine phenylacetate two or three times a day.
14. The method of claim 9 , wherein the immediate release pharmaceutical formulation comprising L-ornithine phenylacetate is administered in a daily dosage of about 8 g to about 10 g.
15. The method of claim 14 , wherein the immediate release pharmaceutical formulation is administered two times a day, each time administering about 4 g to about 5 g L-ornithine phenylacetate.
16. The method of claim 15 , wherein each time the immediate release pharmaceutical formulation is administered in 4 unit dosage forms each comprising about 1 g of L-ornithine phenylacetate.
17. The method of claim 9 , wherein the immediate release pharmaceutical formulation is administered two times a day, each time administering about 4 g to about 6 g L-ornithine phenylacetate.
18. A method for treating or ameliorating hyperammonemia, comprising orally administering to a subject in need thereof an immediate release pharmaceutical formulation comprising L-ornithine phenylacetate in a daily dosage of about 8 g to about 12 g, wherein said administration provides a plasma AUC 0-t or AUC 0-inf of phenylacetic acid ranging from about 100 hr*μg/mL to about 1000 hr*μg/mL.
19. The method of claim 18 , wherein the plasma AUC 0-t or AUC 0-inf of phenylacetic acid is from about 400 hr*μg/mL to about 550 hr*μg/mL.
20. The method of claim 18 , wherein the plasma AUC 0-t or AUC 0-inf of phenylacetylglutamine is from about 25 hr*μg/mL to about 500 hr*μg/mL.
21. The method of claim 20 , wherein the plasma AUC 0-t of phenylacetylglutamine is from about 120 hr*μg/mL to about 180 hr*μg/mL and wherein the plasma AUC 0-inf of phenylacetylglutamine is from about 100 hr*μg/mL to about 250 hr*μg/mL.
22. The method of claim 18 , wherein the subject has liver cirrhosis with a classification of Child-Pugh class A, B or C.
23. The method of claim 18 , wherein the subject has one or more conditions selected from the group consisting of hepatic encephalopathy, portal hypertension, and urea cycle disorder.
24. The method of claim 18 , comprising orally administering 2 to 5 unit dosage forms each comprising from about 0.5 g to about 2 g of L-ornithine phenylacetate two or three times a day.
25. The method of claim 18 , wherein the immediate release pharmaceutical formulation comprising L-ornithine phenylacetate is administered in a daily dosage of about 8 g to about 10 g.
26. The method of claim 25 , wherein the immediate release pharmaceutical formulation is administered two times a day, each time administering about 4 g to about 5 g L-ornithine phenylacetate.
27. The method of claim 26 , wherein each time the immediate release pharmaceutical formulation is administered in 4 unit dosage forms each comprising about 1 g of L-ornithine phenylacetate.
28. The method of claim 18 , wherein the immediate release pharmaceutical formulation is administered two times a day, each time administering about 4 g to about 6 g L-ornithine phenylacetate.